Actively Recruiting
Cohort of Tumors With POLE/D1 Mutation
Led by Federation Francophone de Cancerologie Digestive · Updated on 2024-07-08
100
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary objective of this study is to identify and describe the clinico-biological and molecular characteristics of tumors with somatic POLE (Polymerase ɛ)/POLD1 mutation identified by molecular biology platforms for all stages and primary sites combined
CONDITIONS
Official Title
Cohort of Tumors With POLE/D1 Mutation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Any tumor with a pathogenic variant in the exonuclease domain of POLE (exons 9 to 14), including hotspots at codons 286, 411, 459, and 424
- Any tumor with a pathogenic variant in the exonuclease domain of POLD1 (exons 8 to 12), including C319Y
- Diagnosis made from the cohort launch date or within the previous year
- Age 18 years or older
You will not qualify if you...
- Tumors without POLE or POLD1 mutations
- Tumors with POLE mutations identified only in retrospective research studies
- Patient refusal to allow their data to be included in the cohort
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU -hopital Rangeuil
Toulouse, France, 31059
Actively Recruiting
Research Team
R
ROSINE GUIMBAUD, PhD.MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here